Maine Won\u27t Wait One-Year Progress Report, 2021

This document, an “Maine Climate Science Update 2021”, is an interim communication to the Maine Climate Council and the public about the ongoing work of the scientific community and recent events associated with climate change. It is divided into three sections: (1) current events that reflect the acceleration of extreme weather events in Maine and elsewhere with possible connections to climate change; (2) noteworthy scientific reports with national and international scope released in 2021; and (3) examples of recent peer-reviewed publications from the ongoing work of the scientific community to understand climate change in Maine

Impaired Mineral Ion Metabolism in a Mouse Model of Targeted Calcium-Sensing Receptor (CaSR) Deletion from Vascular Smooth Muscle Cells

Background Impaired mineral ion metabolism is a hallmark of CKD–metabolic bone disorder. It can lead to pathologic vascular calcification and is associated with an increased risk of cardiovascular mortality. Loss of calcium-sensing receptor (CaSR) expression in vascular smooth muscle cells exacerbates vascular calcification in vitro. Conversely, vascular calcification can be reduced by calcimimetics, which function as allosteric activators of CaSR. Methods To determine the role of the CaSR in vascular calcification, we characterized mice with targeted Casr gene knockout in vascular smooth muscle cells (SM22αCaSRΔflox/Δflox). Results Vascular smooth muscle cells cultured from the knockout (KO) mice calcified more readily than those from control (wild-type) mice in vitro. However, mice did not show ectopic calcifications in vivo but they did display a profound mineral ion imbalance. Specifically, KO mice exhibited hypercalcemia, hypercalciuria, hyperphosphaturia, and osteopenia, with elevated circulating fibroblast growth factor 23 (FGF23), calcitriol (1,25-D3), and parathyroid hormone levels. Renal tubular α-Klotho protein expression was increased in KO mice but vascular α-Klotho protein expression was not. Altered CaSR expression in the kidney or the parathyroid glands could not account for the observed phenotype of the KO mice. Conclusions These results suggest that, in addition to CaSR’s established role in the parathyroid-kidney-bone axis, expression of CaSR in vascular smooth muscle cells directly contributes to total body mineral ion homeostasis

Scientific Assessment of Climate Change and Its Effects in Maine

Climate change has already made its presence known in Maine, from shorter winters and warmer summers with ocean heat waves, to stronger storms, new species showing up in our backyards and the Gulf of Maine, aquatic algal blooms, acidic ocean waters that affect shellfish, and new pests and diseases that harm our iconic forests and fisheries. The health of Maine people is also being affected by climate change, from high heat index days driving increased emergency room visits to the ravages of Lyme and other vector-borne diseases. And our economy is feeling the effects, too — with farmers trying to adapt to longer growing seasons but dealing with severe storms and late frosts, aquaculturists already adapting to a more acidic ocean, and winter sports like skiing and snowmobiling being impacted by our shrinking winter season. This is the first report from the Maine Climate Council’s Scientific and Technical Subcommittee, produced by more than 50 scientists from around the State representing Scientific and Technical Subcommittee members, other co-authors, and contributors. This report is part of the 2020 Maine Climate Action Plan. The report summarizes how climate change has already impacted Maine and how it might continue affecting our State in the future

Crop Updates 2001 - Weeds

This session covers forty six papers from different authors: 1. INTRODUCTION, Vanessa Stewart, Agriculture Western Australia PLENARY 2. Wild radish – the implications for our rotations, David Bowran, Centre for Cropping Systems INTEGRATED WEED MANAGEMENT IWM system studies/demonstration sites 3. Integrated weed management: Cadoux, Alexandra Wallace, Agriculture Western Australia 4. A system approach to managing resistant ryegrass, Bill Roy, Agricultural Consulting and Research Services Pty Ltd, York 5. Long term herbicide resistance demonstration, Peter Newman, Agriculture Western Australia, Cameron Weeks, Tony Blake and Dave Nicholson 6. Integrated weed management: Katanning, Alexandra Wallace, Agriculture Western Australia 7. Integrated weed management: Merredin, Vanessa Stewart, Agriculture Western Australia 8. Short term pasture phases for weed control, Clinton Revell and Candy Hudson, Agriculture Western Australia Weed biology – implications for IWM 9. Competitivness of wild radish in a wheat-lupin rotation , Abul Hashem, Nerys Wilkins, and Terry Piper, Agriculture Western Australia 10. Population explosion and persistence of wild radish in a wheat-lupin rotation, Abul Hashem, Nerys Wilkins, Aik Cheam and Terry Piper , Agriculture Western Australia 11. Variation is seed dormancy and management of annual ryegrass, Amanda Ellery and Ross Chapman, CSIRO 12. Can we eradicate barley grass, Sally Peltzer, Agriculture Western Australia Adoption and modelling 13. Where to with RIM? Vanessa Stewart1 and Robert Barrett-Lennard2, 1Agriculture Western Australia, 2Western Australian Herbicide Resistance Initiative (WAHRI) 14. Multi-species RIM model, Marta Monjardino1,2, David Pannell2 and Stephen Powles1 1Western Australian Herbicide Resistance Initiative (WAHRI), 2ARE, University of Western Australia 15. What causes WA grain growers to adopt IWM practices? Rick Llewellyn, WAHRI/ARE, Faculty of Agriculture, University of WA New options for IWM? 16. Fuzzy tramlines for more yield and less weeds, Paul Blackwell Agriculture Western Australia, and Maurice Black, Harbour Lights Estate, Geraldton 17. Inter-row knockdowns for profitable lupins, Paul Blackwell, Agriculture Western Australia and Miles Obst, Farmer Mingenew 18. Row cropping and weed control in lupins, Mike Collins and Julie Roche, Agriculture Western Australia 19. Cross seedimg suppresses annual ryegrass and increases wheat yield, Abul Hashem, Dave Nicholson and Nerys Wilkins Agriculture Western Australia 20. Weed control by chaff burial, Mike Collins, Agriculture Western Australia HERBICIDE RESISTANCE 21. Resistance in wild oats to Fop and Dim herbicides in Western Australia, Abul Hashem and Harmohinder Dhammu, Agriculture Western Australia 22. Triazine and diflufenican resistance in wild radish: what it means to the lupin industry, Aik Cheam, Siew Lee, David Nicholson and Peter Newman, Agriculture Western Australia 23. Comparison if in situ v seed testing for determining herbicide resistance, Bill Roy, Agricultural Consulting and Research Services Pty Ltd, York HERBICIDE TOLERANCE 24. Phenoxy herbicide tolerance of wheat, Peter Newman and Dave Nicholson, Agriculture Western Australia 25. Tolerance of wheat to phenoxy herbicides, Harmohinder S. Dhammu, Terry Piper and Mario F. D\u27Antuono, Agriculture Western Australia 26. Herbicide tolerance of new wheats, Harmohinder S. Dhammu, Terry Piper and David F. Nicholson, Agriculture Western Australia 27. Herbicide tolerance of durum wheats, Harmohinder S. Dhammu, Terry Piper and David F. Nicholson, Agriculture Western Australia 28. Herbicide tolerance of new field pea varieties, Harmohinder S. Dhammu, Terry Piper, David F. Nicholson, and Mario F. D\u27Antuono, Agriculture Western Australia 29. Herbicide tolerance of Cooke field peas on marginal soil, Harmohinder S. Dhammu, Terry Piper, David F. Nicholson, and Mario F. D\u27Antuono, Agriculture Western Australia 30. Herbicide tolerance of some annual pasture legumes adapted to coarse textured sandy soils, Clinton Revell and Ian Rose, Agriculture Western Australia 31 Herbicide tolerance of some annual pasture legumes adapted to fine textured clay soils, Clinton Revell and Ian Rose, Agriculture Western Australia WEED CONTROL IN LUCERNE 32. Management of weeds for Lucerne establishment, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 33. Management of weeds in the second year of Lucerne, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 34. Residual effects of weed management in the third year of Lucerne, Diana Fedorenko, Clayton Butterly, Stuart McAlpine, Terry Piper and David Bowran, Centre for Cropping Systems, Agriculture Western Australia 35. Herbicide tolerance and weed control in Lucerne, Peter Newman, Dave Nicholson and Keith Devenish Agriculture Western Australia HERBICIDES – NEW PRODUCTS/PRODUCE USES; USE New products or product use 36. New herbicide options for canola, John Moore and Paul Matson, Agriculture Western Australia 37. Chemical broadleaf weed management in Peaola, Shannon Barraclough and Lionel Martin, Muresk Institute of Agriculture, Curtin University of Technology 38. Balance® - a new broad leaf herbicide for the chickpea industry, Mike Clarke, Jonas Hodgson and Lawrence Price, Aventis CropScience 39. Marshmallow – robust herbicide strategies, Craig Brown, IAMA Agribusiness 40. Affinity DF – a prospective option for selective in-crop marshmallow control, Gordon Cumming, Technical Officer, Crop Care Australasia 41. A new formulation of Carfentrazone-ethyl for pre-seeding knockdown control of broadleaved weeds including Marshmallow, Gordon Cumming, Technical Officer, Crop Care Australasia Herbicide use 42. Autumn applied trifluralin can be effective! Bill Crabtree, Scientific Officer, Western Australian No-Tillage Farmers Association 43. Which knockdown herbicide for small ryegrass? Peter Newman and Dave Nicholson, Agriculture Western Australia 44. Poor radish control with Group D herbicides in lupins, Peter Newman and Dave Nicholson, Agriculture Western Australia WEED ISSUES 45. Distribution and incidence of aphids and barley yellow dwarf virus in over-summering grasses in the WA wheatbelt, Jenny Hawkes and Roger Jones, CLIMA and Agriculture Western Australia 46. e-weed, Vanessa Stewart, Agriculture Western Australia CONTRIBUTING AUTHOR CONTACT DETAIL

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Sequencing three crocodilian genomes to illuminate the evolution of archosaurs and amniotes

The International Crocodilian Genomes Working Group (ICGWG) will sequence and assemble the American alligator (Alligator mississippiensis), saltwater crocodile (Crocodylus porosus) and Indian gharial (Gavialis gangeticus) genomes. The status of these projects and our planned analyses are described

Prevalence and architecture of de novo mutations in developmental disorders.

The genomes of individuals with severe, undiagnosed developmental disorders are enriched in damaging de novo mutations (DNMs) in developmentally important genes. Here we have sequenced the exomes of 4,293 families containing individuals with developmental disorders, and meta-analysed these data with data from another 3,287 individuals with similar disorders. We show that the most important factors influencing the diagnostic yield of DNMs are the sex of the affected individual, the relatedness of their parents, whether close relatives are affected and the parental ages. We identified 94 genes enriched in damaging DNMs, including 14 that previously lacked compelling evidence of involvement in developmental disorders. We have also characterized the phenotypic diversity among these disorders. We estimate that 42% of our cohort carry pathogenic DNMs in coding sequences; approximately half of these DNMs disrupt gene function and the remainder result in altered protein function. We estimate that developmental disorders caused by DNMs have an average prevalence of 1 in 213 to 1 in 448 births, depending on parental age. Given current global demographics, this equates to almost 400,000 children born per year

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment

Abstracts from the NIHR INVOLVE Conference 2017

n/

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention